A case-control study found that patients with systemic lupus erythematosus (SLE) show a high prevalence of brain alterations that are clinically associated with cerebral small vessel disease (SVD) — a potential cause of strokes — although a clear link between SLE and SVD was not established. SLE is an inflammatory autoimmune disease…
News
Neovacs announced that it has enrolled the first patient in the United States in its expanded, Phase 2b global clinical trial evaluating IFNalpha-Kinoid, a therapeutic vaccine, to treat systemic lupus erythematosus (SLE). The trial (NCT02665364), which began in September 2015, has attracted the interest of American clinical centers and autoimmune…
Aurinia Pharmaceuticals will take its drug candidate voclosporin into a possibly pivotal Phase 3 clinical trial of its efficacy in treating lupus nephritis — kidney disease caused by systemic lupus erythematosus. Following Phase 2 study meetings with the U.S. Food and Drug Administration (FDA), Aurinia believes the new trial will provide…
Merck KGaA announced that it will present two posters showing positive clinical data for its drug candidate atacicept, a recombinant fusion protein for the treatment of systemic lupus erythematosus (SLE). The presentations will take place at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Washington, D.C., which opens on Friday and runs through…
Scientists found a natural protein in immune cells, called CD72, that prevents the abnormal and damaging immune responses characteristic of autoimmune diseases, such as systemic lupus erythematosus (SLE). Findings in the study, “CD72 negatively regulates B lymphocyte responses to the lupus-related endogenous toll-like receptor 7 ligand Sm/RNP,” recently published in The…
We love food. We salivate over it as we watch television commercials, spend hours enjoying it as we dine out with friends and family. And, if we fancy ourselves chefs, we spend time pouring over new recipes and finding new flavors. Still, we don’t always take into…
An independent Data Safety Monitoring Board (DSMB) established by Biotest has recommended the company begin part 2 of its Phase 2a clinical study assessing BT-063, a monoclonal antibody for the treatment of systemic lupus erythematosus (SLE). The DSMB recommendation follows positive interim results. Study 990 (NCT02554019) is a Phase 2…
The Oklahoma Medical Research Foundation (OMRF), an independent non-profit biomedical research institute, will enter a new research collaboration with Eisai, an oncology and neurology-oriented pharmaceutical, to study the genetics of lupus. In lupus patients, the immune system becomes unbalanced and attacks the body’s own tissues. This might lead…
Selexis recently signed an agreement that grants ImmuNext access to the company’s cell lines in order to advance an antibody being developed to treat systemic lupus erythematosus and other autoimmune conditions. Geneva-based Selexis focuses on the development of specific mammalian cells, called CHO-K1, which are adapted to growth in suspension. The cell lines which…
The Lupus Foundation of America (LFA) announced the launch of its latest crowdfunding campaign to raise money for lupus research: The “Cut it Out” 14-day challenge to end lupus. A diagnosis of lupus can be life-altering. Many patients are seriously affected by their disrupted lifestyle following diagnosis. The name…
Recent Posts
- Tracking my sleep, stress, and daily habits is helping me take back control
- FDA fast-tracks experimental daily pill for lupus brain fog issues
- How becoming a pen pal and writing letters can combat isolation
- Accepting help allows us to preserve our health and energy
- Experimental skin lupus therapy dropped after trial misses main goal